Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The Pharmacological Blockade of Phosphodiesterase IV Potentiates the Anti-Tumor Effects of Arsenic Trioxide (ATO) in Acute Myelogenous Leukemia Cells through Multiple Signaling Pathways

Laura Mazzera, PhD, Manuela Abeltino, PhD, Antonio Bonati, MD, Paolo Lunghi, PhD

Blood (2017) 130 (Supplement 1): 2520.

https://doi.org/10.1182/blood.V130.Suppl_1.2520.2520

Published: 2017

Journal Articles

Pan-Aurora Kinases and TRAIL Combination Therapy Has Potent Antitumor Activity In Vivo Against Drug-Resistant Human Multiple Myeloma Xenograft Model

Paolo Lunghi, PhD, Laura Mazzera, Guerino Lombardi, Micaela Ricca, Manuela Abeltino, Davide Arienti, Anna Maria Cantoni, Attilio Corradi, Antonio Bonati, MD

Blood (2011) 118 (21): 1846.

https://doi.org/10.1182/blood.V118.21.1846.1846

Published: 2011

Journal Articles

Blockade of Aurora Kinase Activity Enhances Apo2L/TRAIL Sensitivity In Multiple Myeloma

Paolo Lunghi, PhD, Laura Mazzera, Manuela Abeltino, Nicola Giuliani, Antonio Bonati, MD

Blood (2010) 116 (21): 4059.

https://doi.org/10.1182/blood.V116.21.4059.4059

Published: 2010

Journal Articles

MEK1 Blockade Sensitizes Multiple Myeloma Tumor Cells to Arsenic Trioxide (ATO)-Induced Apoptosis: A Functional and Molecular Study.

Paolo Lunghi, PhD, Nicola Giuliani, MD, Laura Mazzera, PhD, Francesca Morandi, PhD, Vittorio Rizzoli, MD, Antonio Bonati, MD

Blood (2006) 108 (11): 1372.

https://doi.org/10.1182/blood.V108.11.1372.1372

Published: 2006

Journal Articles

Mdm2 Inhibitor Nutlin-3 Enhances the Cytotoxic Synergism Induced by the Combination of MEK1 Inhibitor and Arsenic Trioxide (ATO) in AML Cells.

Paolo Lunghi, PhD, Laura Mazzera, PhD, Vittorio Rizzoli, MD, Antonio Bonati, MD

Blood (2006) 108 (11): 1364.

https://doi.org/10.1182/blood.V108.11.1364.1364

Published: 2006

Journal Articles

Arsenic Trioxide (ATO) and MEK1 Inhibitor Activate Apoptotic p73 Pathway in Primary Acute Myelogenous Leukemia Blasts.

Paolo Lunghi, PhD, Antonio Costanzo, MD, Luigi Salvatore, PhD, Nelida Noguera, PhD, Antonio Tabilio, MD, Francesco Lo Coco, MD, Massimo Levrero, MD, Antonio Bonati, MD

Blood (2005) 106 (11): 613.

https://doi.org/10.1182/blood.V106.11.613.613

Published: 2005

NARROW

The Pharmacological Blockade of Phosphodiesterase IV Potentiates the Anti-Tumor Effects of Arsenic Trioxide (ATO) in Acute Myelogenous Leukemia Cells through Multiple Signaling Pathways

Pan-Aurora Kinases and TRAIL Combination Therapy Has Potent Antitumor Activity In Vivo Against Drug-Resistant Human Multiple Myeloma Xenograft Model

Blockade of Aurora Kinase Activity Enhances Apo2L/TRAIL Sensitivity In Multiple Myeloma

MEK1 Blockade Sensitizes Multiple Myeloma Tumor Cells to Arsenic Trioxide (ATO)-Induced Apoptosis: A Functional and Molecular Study.

Mdm2 Inhibitor Nutlin-3 Enhances the Cytotoxic Synergism Induced by the Combination of MEK1 Inhibitor and Arsenic Trioxide (ATO) in AML Cells.

Arsenic Trioxide (ATO) and MEK1 Inhibitor Activate Apoptotic p73 Pathway in Primary Acute Myelogenous Leukemia Blasts.

Email alerts

ASH Publications

American Society of Hematology

The Pharmacological Blockade of Phosphodiesterase IV Potentiates the Anti-Tumor Effects of Arsenic Trioxide (ATO) in Acute Myelogenous Leukemia Cells through Multiple Signaling Pathways

Pan-Aurora Kinases and TRAIL Combination Therapy Has Potent Antitumor Activity In Vivo Against Drug-Resistant Human Multiple Myeloma Xenograft Model

Blockade of Aurora Kinase Activity Enhances Apo2L/TRAIL Sensitivity In Multiple Myeloma

MEK1 Blockade Sensitizes Multiple Myeloma Tumor Cells to Arsenic Trioxide (ATO)-Induced Apoptosis: A Functional and Molecular Study.

Mdm2 Inhibitor Nutlin-3 Enhances the Cytotoxic Synergism Induced by the Combination of MEK1 Inhibitor and Arsenic Trioxide (ATO) in AML Cells.

Arsenic Trioxide (ATO) and MEK1 Inhibitor Activate Apoptotic p73 Pathway in Primary Acute Myelogenous Leukemia Blasts.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only